Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BioHarvest Sciences ( (BHST) ) just unveiled an announcement.
BioHarvest Sciences has secured a $1.6 million non-dilutive grant from the Israeli Innovation Authority’s Bio-Convergence program to advance its second-generation Botanical Synthesis platform. The zero-interest funding will be used to integrate artificial intelligence for process optimization, increase bioreactor size for higher-volume production and better unit economics, and expand autonomous manufacturing capabilities to enhance scalability and operational efficiency. Recognized by the Authority for its differentiated plant cell culture approach, BioHarvest underscores that it is already fully funded for its current strategic plans with roughly $25 million in cash, and the grant further bolsters its balance sheet by financing advanced R&D without shareholder dilution, with repayment tied only to future revenues from the funded project upon achieving commercial milestones.
The most recent analyst rating on (BHST) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
BioHarvest Sciences faces significant challenges with profitability and financial stability, reflected in a low financial performance score. The technical analysis indicates a bearish trend, and the valuation is unattractive due to negative earnings. While the earnings call provided some positive insights, the overall outlook remains cautious.
To see Spark’s full report on BHST stock, click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc., listed on Nasdaq and the Frankfurt Stock Exchange, is a biotechnology company specializing in its proprietary Botanical Synthesis platform, which produces plant-based active compounds via controlled plant cell culture rather than traditional agriculture. The company operates as both a contract development and production organization for customers seeking novel plant-derived compounds and as a developer of proprietary nutraceutical health and wellness products, including dietary supplements, targeting science-based and clinically supported therapeutic solutions.
Average Trading Volume: 98,818
Technical Sentiment Signal: Buy
Current Market Cap: $124.6M
See more insights into BHST stock on TipRanks’ Stock Analysis page.